1 not yet recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow ARCE Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies Non interventional study - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory | Not yet recruiting | ARCE Therapeutics, Inc. | 49 | 2026-03-15 | 2025-12-08 | |
| Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS ARD103, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Recruiting | ARCE Therapeutics, Inc. | 49 | 2025-05-20 | 2025-12-10 |
Anemia, Refractory, with Excess of Blasts (2) · Leukemia, Myeloid, Acute (2)
Cyclophosphamide (1) · fludarabine (1)
United States (2)